NCT/Study#

NCT03229200 /

PCYC-1145-LT

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

DISEASE GROUP:
Lymphoma
current phase:
NA
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: